Rational Pharmacotherapy in Cardiology

Advanced search


Full Text:


Statins are lipid-lowering drugs with proven efficacy that reduce cardiovascular risk and are well tolerated by most patients. Myopathy as a side effect of statin therapy is one of the most common reasons for their withdrawal. Its severity can range from asymptomatic increase of serum CPK to life-threatening rhabdomyolysis. Therefore it is necessary to remember about the possibility of its occurrence.

The exact molecular mechanisms of muscle damage by statins are still unknown. Various hypotheses are suggested in this respect: fatty acid oxidation disorders, mitochondrial dysfunction, increased protein degradation in myocytes due to changes in atrogin-1 and ubiquitin activity, activation of autoimmune processes, intracellular depletion of essential metabolites, destabilization of cell membranes, impaired expression of genes involved in apoptosis and protein degradation. The theory that the reduction of intramuscular CoQ10 level is the cause of myopathy prevails. Additional intake of CoQ10 seems promising, but is not evidence-based.

About the Authors

O. M. Drapkina
I.M. Sechenov First Moscow Medical University
Russian Federation

Trubetskaya ul. 8-2, Moscow, 119991 Russia

E. M. Chernova
I.M. Sechenov First Moscow Medical University
Russian Federation

Trubetskaya ul. 8-2, Moscow, 119991 Russia


1. Foley KA, Simpson RJ Jr., Crouse JR 3rd., et al. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003; 92:79-81.

2. O’Meara JG, Kardia SL, Armon JJ, et al. Ethnic and sex differences in the prevalence, treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. Arch Intern Med 2004; 164:1313-8.

3. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288:462-7.

4. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-16.

5. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-35.

6. Buettner C, Davis RB, Leveille SG, et al. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med 2008; 23:1182-6.

7. Arora R, Liebo M, Maldonado F. Statin-induced myopathy: the two faces of Janus. // J Cardiovasc Pharmacol Ther 2006;11(2):105-12.

8. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007;9(5):389-96.

9. Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs 2008;8(6):373-418.

10. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007;9(5):389-96.

11. Harper CR, Jacobson TA. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol 2007;18(4):401-8.

12. Meador BM, Huey KA. Statin-associated myopathy and its exacerbation with exercise. Muscle Nerve 2010;42(4):469-79.

13. Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol 2006;291(6):C1208-12.

14. Di Stasi SL, MacLeod TD, Winters JD, Binder-Macleod SA. Effects of statins on skeletal muscle: a perspective for physical therapists. Phys Ther 2010;90(10):1530-42.

15. Evans M, Rees A. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002;25(9):649-63.

16. Toth PP, Harper CR, Jacobson TA. Clinical characterization and molecular mechanisms of statin myopathy. Expert Rev Cardiovasc Ther 2008;6(7):955-69.

17. Christopher-Stine L. Statin myopathy: an update. Curr Opin Rheumatol 2006;18(6):647-53.

18. Phillips PS, Haas RH. Statin myopathy as a metabolic muscle disease. Expert Rev Cardiovasc Ther 2008;6(7):971-8.

19. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009;150(12):858-68.

20. Arca M, Pigna G. Treating statin-intolerant patients. Diabetes Metab Syndr Obes 2011;4:155-66.

21. Littarru GP, Langsjoen P. Coenzyme Q10 and statins: biochemical and clinical implications. Mitochondrion 2007;7 Suppl:S168-74.

22. Marcoff L, Thompson PD. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. J Am Coll Cardiol 2007;49(23):2231-7.

23. PäiväH, Thelen KM, Van Coster R, et al. High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial. Clin Pharmacol Ther 2005;78(1):60-8.

24. Suzuki T, Nozawa T, Sobajima M, et al. Atorvastatin-induced changes in plasma coenzyme q10 and brain natriuretic peptide in patients with coronary artery disease. Int Heart J 2008;49(4):423-33.

25. Lamperti C, Naini AB, Lucchini V, et al. Muscle coenzyme Q10 level in statin-related myopathy. Arch Neurol 2005;62(11):1709-12.

26. Laaksonen R, Jokelainen K, Sahi T, et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. // Clin Pharmacol Ther 1995;57(1):62-6.

27. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007;99(10):1409-12.

28. Young JM, Florkowski CM, Molyneux SL, et al. Effect of coenzyme Q(10) supplementation on simvastatininduced myalgia. Am J Cardiol 2007;100(9):1400-3.

29. Roberts WC The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997; 80:106-7.

30. Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003; 92:23K-29K.

31. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003; 289:1681-90.

32. Glueck CJ, Aregawi D, Agloria M, et al. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Clin Ther 2006; 28:933-42.

33. Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008; 42:341-6.

34. Backes JM, Moriarty PM, Ruisinger JF, et al. Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol 2007; 100:554-5.

35. Kjekshus J, Dunselman P, Blideskog M, et al.; CORONA Study Group. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005;7(6):1059-69.

36. Kjekshus J, Apetrei E, Barrios V, et al.; CORONA Group. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357(22):2248-61.

For citation:

Drapkina O.M., Chernova E.M. MYOPATHY AS A SIDE EFFECT OF STATIN THERAPY: MECHANISMS OF DEVELOPMENT AND PROSPECTS FOR TREATMENT. Rational Pharmacotherapy in Cardiology. 2015;11(1):96-101. (In Russ.)

Views: 741

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)